Cardiac natriuretic peptides and obesity: Perspectives from an endocrinologist and a cardiologist

Endocrine Connections

Volumn 4, Issue 3, 2015, Pages R25-R36

  Ramos, Hugo R ^a   Birkenfeld, Andreas L ^b,c   De Bold, Adolfo J ^d  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

ANF; ANP; BNP; Heart disease; Natriuretic peptides; NT proBNP; Obesity

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; CYTOKINE; ENDOTHELIN 1; GLUCAGON LIKE PEPTIDE 1; GROWTH FACTOR; INSULIN; MEMBRANE METALLOENDOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR C; NEUTROPHIL ACTIVATING PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEINASE; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

ADIPOSE TISSUE; BLOOD PRESSURE; CARDIOLOGIST; ENDOCRINOLOGIST; HUMAN; LIPID OXIDATION; LIPOLYSIS; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECRETION (PROCESS); STIMULUS; SYSTOLIC HEART FAILURE; VASCULAR DISEASE;

EID: 84992393515     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-15-0018     Document Type: Review

References (135)

1. Ogawa T & de Bold AJ. The heart as an endocrine organ. Endocrine Connections 2014 3 R31-R44. (doi:10.1530/EC-14-0012).
2. Ramos H & de Bold AJ. Gene expression, processing and secretion of natriuretic peptides: physiologic and diagnostic implications. Heart Failure Clinics 2006 2 255-268. (doi:10.1016/j.hfc.2006.08.005).
3. Kuroski de Bold ML & de Bold AJ. Stretch-secretion coupling in atrial cardiocytes. Dissociation between atrial natriuretic factor release and mechanical activity. Hypertension 1991 18 III-169-III-178. (doi:10.1161/01.HYP.18.5_Suppl.III169).
4. Meirovich YF, Veinot JP, de Bold ML, Haddad H, Davies RA, Masters RG, Hendry PJ & de Bold AJ. Relationship between natriuretic peptides and inflammation: proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. Journal of Heart and Lung Transplantation 2008 27 31-37. (doi:10.1016/j.healun.2007. 09.025).
5. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y & Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology 2006 47 742-748. (doi:10.1016/j.jacc.2005.11.030).
6. Maeder MT, Mariani JA & Kaye DM. Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress. Hypertension 2010 56 682-689. (doi:10.1161/HYPERTENSIONAHA.110.156547).
7. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ & de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999 100 287-291. (doi:10.1161/01.CIR.100.3.287).
8. El Gamel A, Yonan NA, Keevil B, Warbuton R, Kakadellis J, Woodcock A, Campbell CS, Rahman AN & Deiraniya AK. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Annals of Thoracic Surgery 1997 63 1095-1100. (doi:10.1016/S0003-4975(97)00168-9).
9. Talha S, Charloux A, Enache I, Piquard F & Geny B. Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. Cardiovascular Research 2011 89 273-281. (doi:10.1093/cvr/cvq331).
10. Gimelli A, Lancellotti P, Badano LP, Lombardi M, Gerber B, Plein S, Neglia D, Edvardsen T, Kitsiou A, Scholte AJ et al. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). European Heart Journal 2014 35 3417-3425. (doi:10.1093/ eurheartj/ehu433).
11. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2012 14 803-869. (doi:10.1093/eurjhf/hfs033).
12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 128 e240-e327. (doi:10.1161/CIR.0b013e31829e8807).
13. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM & Burnett JC Jr. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006 47 874-880. (doi:10.1161/01.HYP. 0000216794.24161.8c).
14. Galasko GI, Lahiri A, Barnes SC, Collinson P & Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? European Heart Journal 2005 26 2269-2276. (doi:10.1093/eurheartj/ehi410).
15. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA & Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine 2004 350 655-663. (doi:10.1056/NEJMoa031994).
16. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ & Cowie MR. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. European Journal of Heart Failure 2005 7 537-541. (doi:10.1016/j.ejheart.2005.01.022).
17. Mogelvang R, Goetze JP, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Sogaard P & Jensen JS. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. Journal of Cardiac Failure 2009 15 489-495. (doi:10.1016/j.cardfail.2009.01.005).
18. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Schnohr P & Jensen JS. Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study. European Heart Journal 2009 30 731-739. (doi:10.1093/ eurheartj/ehn596).
19. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF & Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004 109 594-600. (doi:10.1161/01.CIR.0000112582. 16683.EA).
20. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT, Steg PG, Omland T, Knudsen CW, Sandberg KR et al. Relationship between obesity and B-type natriuretic peptide levels. Archives of Internal Medicine 2004 164 2247-2252. (doi:10.1001/ archinte.164.20.2247).
21. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. American Heart Journal 2006 151 999-1005. (doi:10.1001/archinte.164.20.2247).
22. Nakane T, Kawai M, Komukai K, Kayama Y, Matsuo S, Nagoshi T, Minai K, Date T, Ogawa T, Yagi H et al. Contribution of extracardiac factors to the inconsistency between plasma B-type natriuretic peptide levels and the severity of pulmonary congestion on chest X-rays in the diagnosis of heart failure. Internal Medicine 2012 51 239-248. (doi:10.2169/internalmedicine.51.6206).
23. Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloshchitsyna MN, Koshkina EV, KrasnoselskyMI, Serebryanaya DV & Katrukha AG. Processing of pro-brain natriuretic peptide Is suppressed by O-glycosylation in the region close to the cleavage site. Clinical Chemistry 2009 3 489-498. (doi:10.1373/clinchem.2008.113373).
24. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr & Ikeda Y. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clinical Chemistry 2011 57 864-873. (doi:10.1373/clinchem. 2010.157438).
25. Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. European Heart Journal 2014 35 3434-3441. (doi:10.1093/ eurheartj/ehu314).
26. Giuliani I, Rieunier F, Larue C, Delagneau JF, Granier C, Pau B, Ferriere M, Saussine M, Cristol JP, Dupuy AM et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clinical Chemistry 2006 52 1054-1061. (doi:10.1373/clinchem. 2005.061770).
27. Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K et al. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. Journal of the American College of Cardiology 2011 57 1386-1395. (doi:10.1016/j.jacc.2011.01.005).
28. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine 2014 371 993-1004. (doi:10.1056/ NEJMoa1409077).
29. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J,McKelvie RS et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004 110 2618-2626. (doi:10.1161/01.CIR.0000146819.43235.A9).
30. Cohn JN & Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001 345 1667-1675. (doi:10.1056/NEJMoa010713).
31. Bohm M, Pogue J, Kindermann I, Poss J, Koon T & Yusuf S. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. European Journal of Heart Failure 2014 16 325-333. (doi:10.1002/ejhf.23).
32. Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S et al. Effects of longterm enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. Circulation 1993 88 481-491. (doi:10.1161/01.CIR.88.2.481).
33. Samocha-Bonet D, Dixit VD, Kahn CR, Leibel RL, Lin X, NieuwdorpM, Pietilainen KH, Rabasa-Lhoret R, Roden M, Scherer PE et al. Metabolically healthy and unhealthy obese - the 2013 Stock Conference report. Obesity Reviews 2014 15 697-708. (doi:10.1111/obr.12199).
34. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM & Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 1640-1645. (doi:10.1161/CIRCULATIONAHA.109.192644).
35. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A & Haring HU. Identification and characterization of metabolically benign obesity in humans. Archives of Internal Medicine 2008 168 1609-1616. (doi:10.1001/archinte.168. 15.1609).
36. Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE & Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. Journal of the American College of Cardiology 2014 63 1071-1078. (doi:10.1016/j.jacc.2013.11.035).
37. Wirth J, Buijsse B, di GR, Fritsche A, Hense HW, Westphal S, Isermann B, Boeing H & Weikert C. Relationship between N-terminal pro-brain natriuretic peptide, obesity and the risk of heart failure in middle-aged german adults. PLoS ONE 2014 9 e113710. (doi:10.1371/ journal.pone.0113710).
38. Zastrow A, Wolf J, Giannitsis E, Katus H, Herzog W, Friederich HC & Mussler C. Elevated myocardial enzymes and natriuretic peptides in anorexia nervosa: prototypic condition for the pathophysiology of cachexia? Cardiology 2011 118 256-259. (doi:10.1159/000329512).
39. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC & Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013 347 f5934. (doi:10.1136/ bmj.f5934).
40. Wikiel KJ, McCloskey CA & Ramanathan RC. Bariatric surgery: a safe and effective conduit to cardiac transplantation. Surgery for Obesity and Related Diseases 2014 10 479-484. (doi:10.1016/j.soard.2013.11.002).
41. Johnson BL, Blackhurst DW, Latham BB, Cull DL, Bour ES, Oliver TL, Williams B, Taylor SM & Scott JD. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. Journal of the American College of Surgeons 2013 216 545-556. (doi:10.1016/j.jamcollsurg.2012.12.019).
42. Chaudhry UI, Kanji A, Sai-Sudhakar CB, Higgins RS & Needleman BJ. Laparoscopic sleeve gastrectomy in morbidly obese patients with endstage heart failure and left ventricular assist device: medium-term results. Surgery for Obesity and Related Diseases 2015 11 88-93. (doi:10.1016/j.soard.2014.04.003).
43. Miranda WR, Batsis JA, Sarr MG, Collazo-Clavell ML, Clark MM, Somers VK & Lopez-Jimenez F. Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure. Obesity Surgery 2013 23 1011-1015. (doi:10.1007/s11695-013- 0953-8).
44. Alpert MA, Nusair MB, Mukerji R, Omran J, Mehra A, Ardhanari S, Kumar SA & Terry BE. Effect of weight loss on ventricular repolarization in normotensive severely obese patients with and without heart failure. American Journal of the Medical Sciences 2015 349 17-23. (doi:10.1097/MAJ.0000000000000342).
45. Vest AR & Young JB. Should we target obesity in advanced heart failure? Current Treatment Options in Cardiovascular Medicine 2014 16 284. (doi:10.1007/s11936-013-0284-z).
46. Abrahamsson N, Engstrom BE, Sundbom M & Karlsson FA. Gastric bypass surgery elevates NT-ProBNP levels. Obesity Surgery 2013 23 1421-1426. (doi:10.1007/s11695-013-0889-z).
47. Arjamaa O & Nikinmaa M. Hypoxia regulates the natriuretic peptide system. International Journal of Physiology, Pathophysiology and Pharmacology 2011 3 191-201.
48. Magga J, Marttila M, Mäntymaa P, Vuolteenaho O & Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994 134 2505-2515.
49. Tateishi J, MasutaniM, OhyanagiM& Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clinical Cardiology 2000 23 776-780. (doi:10.1002/clc.4960231016).
50. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG & Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003 107 2786-2792. (doi:10.1161/01.CIR.0000070953.76250.B9).
51. Kragelund C, Gronning B, Kober L, Hildebrandt P & Steffensen R. N-terminnal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine 2005 352 666-675. (doi:10.1056/NEJMoa042330).
52. Mishra RK, Beatty AL, Jaganath R, Regan M, Wu AH & Whooley MA. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Journal of the American Heart Association 2014 3 e000907. (doi:10.1161/JAHA.114.000907).
53. Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, Levy D, Vasan RS & Wang TJ. Reference limits for N-terminal-pro-Btype natriuretic peptide in healthy individuals (from the Framingham Heart Study). American Journal of Cardiology 2011 108 1341-1345. (doi:10.1016/j.amjcard.2011.06.057).
54. Nordenskjold AM, Ahlstrom H, Eggers KM, Frobert O, Venge P & Lindahl B. Short- and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease. Clinica Chimica Acta 2013 422 15-20. (doi:10.1016/j.cca.2013.03.025).
55. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, Mannucci PM, Mininni N, Prando MD, TubaroMet al. N-terminal probrain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004 110 128-134. (doi:10.1161/01.CIR.0000134480.06723.D8).
56. Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, Campos A,Gamarski R, Masetto AC&MoutinhoMA. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. European Heart Journal 2005 26 234-240. (doi:10.1093/eurheartj/ehi033).
57. Bassan R, Tura BR & Maisel AS. B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department. Coronary Artery Disease 2009 20 143-149. (doi:10.1097/MCA. 0b013e3283292ac6).
58. Melki D, Lind S, Agewall S& Jernberg T. Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. Clinica Chimica Acta 2012 413 933-937. (doi:10.1016/j.cca.2012.02.008).
59. Foote RS, Pearlman JD, Siegel AH & Yeo KT. Detection of exerciseinduced ischemia by changes in B-type natriuretic peptides. Journal of the American College of Cardiology 2004 44 1980-1987. (doi:10.1016/ j.jacc.2004.08.045).
60. WeberM, Bazzino O, NavarroEstrada JL, Fuselli JJ, Botto F, Perezde AD, Mollmann H, Nef HN, Elsasser A & Hamm CW. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. Journal of the American College of Cardiology 2008 51 1188-1195. (doi:10.1016/j.jacc.2007.11.054).
61. Truong QA, Bayley J, Hoffmann U, Bamberg F, Schlett CL, Nagurney JT, Koenig W & Januzzi JL. Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial. American Heart Journal 2012 163 972-979. (doi:10.1016/ j.ahj.2012.03.010).
62. Garcia-Alvarez A, Regueiro A, Hernandez J, Kasa G, Sitges M, Bosch X & Heras M. Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome. European Heart Journal. Acute Cardiovascular Care 2014 3 132-140. (doi:10.1177/ 2048872614520753).
63. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/ American Heart Association TASK Force on Practice Guidelines. Journal of the American College of Cardiology 2014 64 e139-e228. (doi:10.1016/j.jacc.2014.09.017).
64. Bjorklund E, Jernberg T, Johanson P, Venge P, DellborgM,Wallentin L & Lindahl B. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006 92 735-740. (doi:10.1136/hrt.2005.072975).
65. Scirica BM, Kadakia MB, de Lemos JA, Roe MT, Morrow DA, Li S, Wiviott SD & Kontos MC. Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG. Clinical Chemistry 2013 59 1205-1214. (doi:10.1373/clinchem.2012.198556).
66. Schellings DA, Adiyaman A, Giannitsis E, Hamm C, Suryapranata H, ten Berg JM, Hoorntje JC & Van't Hof AW. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score. Journal of the American Heart Association 2014 3 e001089. (doi:10.1161/ JAHA.114.001089).
67. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG & Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995 267 679-681. (doi:10.1126/science.7839143).
68. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S et al. Genome-wide association study identifies eight loci associated with blood pressure. Nature Genetics 2009 41 666-676. (doi:10.1038/ng.361).
69. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nature Genetics 2009 41 348-353. (doi:10.1038/ng.328).
70. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormonesANPandBNP. Journal of theAmerican College of Cardiology 2012 60 1558-1565. (doi:10.1016/j.jacc.2012.05.049).
71. de Bold MK, Sheffield WP, Martinuk A, Bhakta V, Eltringham-Smith L & de Bold AJ. Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Regulatory Peptides 2012 175 7-10. (doi:10.1016/j.regpep. 2012.01.005).
72. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 2005 112 836-840. (doi:10.1161/CIRCULATIONAHA.105.538520).
73. Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC & Burnett JC Jr. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clinic Proceedings 2012 87 413-415. (doi:10.1016/j.mayocp.2012.02.003).
74. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D,Wians FH Jr et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005 112 2163-2168. (doi:10.1161/CIRCULATIONAHA.105.555573).
75. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jorgensen T & Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005 46 660-666. (doi:10.1161/01.HYP.0000179575. 13739.72).
76. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. Journal of Clinical Endocrinology and Metabolism 2011 96 3242-3249. (doi:10.1210/jc.2011-1182).
77. Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y & Yoshimasa Y. Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study. Endocrine Journal 2010 57 727-733. (doi:10.1507/endocrj.K10E-067).
78. Cannone V, Cefalu' AB, Noto D, Scott CG, Bailey KR, Cavera G, Pagano M, Sapienza M, Averna MR & Burnett JC Jr. The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. Diabetes Care 2013 36 2850-2856. (doi:10.2337/dc12-2337).
79. Stavrakis S, Pakala A, Thomas J, Chaudhry MA & Thadani U. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. American Journal of the Medical Sciences 2013 345 211-217. (doi:10.1097/MAJ.0b013e318271c012).
80. Kenny AJ, Bourne A & Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochemical journal 1993 291 83-88.
81. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA & Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 1987 238 675-678. (doi:10.1126/ science.2823385).
82. Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E & Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. Journal of Endocrinological Investigation 1996 19 581-585. (doi:10.1007/BF03349021).
83. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? Journal of Clinical Endocrinology and Metabolism 2012 97 E731-E739. (doi:10.1210/jc.2011-2839).
84. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T& Shimomura I. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochemical and Biophysical Research Communications 2010 392 100-105. (doi:10.1016/j.bbrc.2010.01.008).
85. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, Giantomassi L & Rappelli A. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. Journal of Hypertension 1997 15 1695-1699. (doi:10.1097/00004872-199715120-00074).
86. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM et al. Neprilysin, obesity and the metabolic syndrome. International Journal of Obesity 2011 35 1031-1040. (doi:10.1038/ijo.2010.227).
87. Jung DY, Ha H, Lee E, Hu X, Tran DA, Tsitsilianos N, Tsitsilianos AV, Garvin AC, Hsu K, Binny MH et al. BNP is a novel cardiomyokine that regulates hepatic inuslin action in diet induced obese mice. Diabetes (Supplement 1) 2014 63 37-OR.
88. Stamler R, Stamler J, Riedlinger WF, Algera G & Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. Journal of the American Medical Association 1978 240 1607-1610. (doi:10.1001/jama.1978.03290150053024).
89. Aneja A, El-Atat F, McFarlane SI & Sowers JR. Hypertension and obesity. Recent Progress in Hormone Research 2004 59 169-205. (doi:10.1210/rp.59.1.169).
90. Jordan J & Engeli S. Obesity, hypertension, and cardiovascular health: is there anything poor Cassandra tries to tell us? Journal of Hypertension 2012 30 1103-1105. (doi:10.1097/HJH.0b013e3283542da0).
91. Clinkingbeard C, Sessions C & Shenker Y. The physiological role of atrial natriuretic hormone in the regulation of aldosterone and salt and water metabolism. Journal of Clinical Endocrinology and Metabolism 1990 70 582-589. (doi:10.1210/jcem-70-3-582).
92. Bruun NE, Dige-Pedersen H & Skott P. Normal responses of atrial natriuretic factor and renal tubular function to sodium loading in hypertension-prone humans. Blood Pressure 2000 9 206-213. (doi:10.1080/080370500439092).
93. Uehlinger DE, Zaman T, Weidmann P, Shaw S & Gnadinger MP. Pressure dependence of atrial natriuretic peptide during norepinephrine infusion in humans. Hypertension 1987 10 249-253. (doi:10.1161/01.HYP.10.3.249).
94. Park BM, Oh YB, Gao S, Cha SA, Kang KP & Kim SH. Angiotensin III, stimulates high stretch-induced ANP secretion via angiotensin type 2 receptor. Peptides 2013 42 131-137. (doi:10.1016/j.peptides. 2013.01.018).
95. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Moller DV, Hedley PL, Christiansen M, Goetze JP, Esler M & Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension 2013 62 147-153. (doi:10.1161/HYPERTENSIONAHA.111.00791).
96. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. Journal of the American College of Cardiology 2006 48 499-505. (doi:10.1016/j.jacc.2005.12.081).
97. Rubattu S, Sciarretta S, Ciavarella GM, Venturelli V, De Paolis P, Tocci G, De Biase L, Ferrucci A & Volpe M. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. Journal of Hypertension 2007 25 833-839. (doi:10.1097/HJH. 0b013e32803cae3c).
98. Sengenes C, Berlan M, De G I, Lafontan M & Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB Journal 2000 14 1345-1351. (doi:10.1096/fj.14.10.1345).
99. Galitzky J, Sengenes C, Thalamas C, Marques MA, Senard JM, LafontanM& Berlan M. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. Journal of Lipid Research 2001 42 536-544.
100. Schlueter N, de Sterke A, Willmes DM, Spranger J, Jordan J & Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacology & Therapeutics 2014 144 12-27. (doi:10.1016/j.pharmthera.2014.04.007).
101. Birkenfeld AL, Adams F, Schroeder C, Engeli S & Jordan J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension 2011 57 e4-e5. (doi:10.1161/HYPERTENSIONAHA.110.165159).
102. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M & Jordan J. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. Journal of Clinical Endocrinology and Metabolism 2005 90 3622-3628. (doi:10.1210/jc.2004-1953).
103. Moro C, Galitzky J, Sengenes C, Crampes F, Lafontan M & Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. Journal of Pharmacology and Experimental Therapeutics 2004 308 984-992. (doi:10.1124/jpet.103.060913).
104. Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC & Jordan J. Atrial natriuretic peptide and adiponectin interactions in man. PLoS ONE 2012 7 e43238. (doi:10.1371/journal.pone.0043238).
105. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A & Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005 112 1756-1762. (doi:10.1161/CIRCULATIONAHA.104.530972).
106. Azizi Ghanbari A, Dorr R, Spitzer S, Stumpf J, Britz A, Amann-Zalan I, Lodwig V, Ulm B, Schnell O & Lohmann T. Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance. Diabetes & Vascular Disease Research 2013 10 452-458. (doi:10.1177/ 1479164113490179).
107. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R & Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. Journal of Clinical Investigation 2012 122 1022-1036. (doi:10.1172/JCI59701).
108. Collins S. A heart-adipose tissue connection in the regulation of energy metabolism. Nature Reviews. Endocrinology 2014 10 157-163. (doi:10.1038/nrendo.2013.234).
109. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Tank J, Diedrich A, Schroeder C, Franke G, Berlan M et al. β-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. Journal of Clinical Endocrinology and Metabolism 2006 91 5069-5075. (doi:10.1210/jc.2006-1084).
110. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, Berlan M, Marques MA, Sweep FC, Luft FC et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 2008 57 3199-3204. (doi:10.2337/db08-0649).
111. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009 58 2880-2892. (doi:10.2337/db09-0393).
112. Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I et al.Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. Journal of Clinical Investigation 2012 122 4675-4679. (doi:10.1172/JCI64526).
113. Birkenfeld AL & Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014 59 713-723. (doi:10.1002/hep.26672).
114. Mitsuishi M, Miyashita K & Itoh H. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochemical and Biophysical Research Communications 2008 367 840-845. (doi:10.1016/j.bbrc.2008.01.017).
115. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003 299 896-899. (doi:10.1126/science.1079368).
116. Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, Jurczak MJ, Zhang D, Woo DK, Shadel GS, Ladiges W et al. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metabolism 2010 12 668-674. (doi:10.1016/j.cmet.2010.11.004).
117. Birkenfeld AL, Lee HY, Guebre-Egziabher F, Alves TC, Jurczak MJ, Jornayvaz FR, Zhang D, Hsiao JJ, Martin-Montalvo A, Fischer- Rosinsky A et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metabolism 2011 14 184-195. (doi:10.1016/ j.cmet.2011.06.009).
118. Perry RJ, Kim T, Zhang XM, Lee HY, Pesta D, Popov VB, Zhang D, Rahimi Y, Jurczak MJ, Cline GW et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metabolism 2013 18 740-748. (doi:10.1016/j.cmet.2013.10.004).
119. Heinisch BB, Vila G, Resl M, RiedlM, Dieplinger B, Mueller T, Luger A, Pacini G & Clodi M. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 2012 55 1400-1405. (doi:10.1007/s00125-011-2392-1).
120. Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, Khera A, McGuire DK, Vega GL, de Lemos JA et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. Journal of the American College of Cardiology 2013 62 752-760. (doi:10.1016/j.jacc.2013.03.038).
121. Everett BM, Cook NR, Chasman DI, Magnone MC, Bobadilla M, Rifai N, Ridker PM & Pradhan AD. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clinical Chemistry 2013 59 557-565. (doi:10.1373/clinchem. 2012.194167).
122. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Medicine 2011 8 e1001112. (doi:10.1371/journal.pmed.1001112).
123. MagnussonM, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, MorgenthalerNG, NilssonP,Newton-ChehC,WangTJ et al.Lowplasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. Journal of Clinical Endocrinology and Metabolism 2012 97 638-645. (doi:10.1210/jc.2011-2425).
124. Martin J, Bergeron S, Pibarot P, Bastien M, Biertho L, Lescelleur O, Bertrand F, Simard S & Poirier P. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Canadian Journal of Cardiology 2013 29 969-975. (doi:10.1016/j.cjca.2012.11.010).
125. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT & Espeland MA. Brain natriuretic peptide subgroup of the look ARG. impact of the look ahead intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity 2012 20 1511-1518. (doi:10.1038/oby.2011.296).
126. Chen-Tournoux A, Khan AM, Baggish AL, Castro VM, Semigran MJ, McCabe EL, Moukarbel G, Reingold J, Durrani S, Lewis GD et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-Btype natriuretic peptide levels. American Journal of Cardiology 2010 106 1450-1455. (doi:10.1016/j.amjcard.2010.06.076).
127. Haufe S, Haas V, Utz W, Birkenfeld AL, Jeran S, Bohnke J, Mahler A, Luft FC, Schulz-Menger J, Boschmann M et al. Long-lasting improvements in liver fat andmetabolismdespite bodyweight regain after dietary weight loss. Diabetes Care 2013 36 3786-3792. (doi:10.2337/dc13-0102).
128. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA & Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nature Medicine 2013 19 567-575. (doi:10.1038/nm.3128).
129. Skov J, Holst JJ, Gotze JP, Frokiaer J & Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connections 2014 3 11-16. (doi:10.1530/EC-13-0087).
130. Lovshin JA, Barnie A, Dealmeida A, Logan A, Zinman B & Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015 38 132-139. (doi:10.2337/dc14-1958).
131. Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S & Yu DM. Changes in liraglutide-induced body composition are related to modifications in plasma cardiacnatriuretic peptides levels in obese type 2 diabetic patients. Cardiovascular Diabetology 2014 13 36. (doi:10.1186/1475-2840-13-36).
132. Haufe S, Kaminski J, Utz W, Haas V, Mahler A, Daniels MA, Birkenfeld AL, Lichtinghagen R, Luft FC & Schulz-Menger J. Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. Journal of Hypertension 2015.
133. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ & Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic metaanalysis in the acute care setting. BMJ 2015 350 h910.
134. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G & Cohn JN. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clinical Chemistry 2006 52 1528-1538.
135. Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y et al. Japanese- Western consensus meeting on biomarkers. International Heart Journal 2011 52 253-265.